Table 1.
SGLT2 inhibitors
| Agent | Company | Brand | Dose mg/day |
SGLT2 IC50 nmol/l |
SGLT1 IC50 nmol/l |
|---|---|---|---|---|---|
| Dapagliflozin | AstraZeneca* | Farxiga | 5, 10 | 1.2 | 1400 |
| Canagliflozin | Janssen, Napp | Invokana | 100, 300 | 2.7 | 710 |
| Empagliflozin | Boehringer Ingelheim, Eli Lilly | Jardiance | 10, 25 | 3.1 | 8300 |
| Ertugliflozin | Merck Sharp & Dohme, Pfizer | Steglatro | 5, 15 | 0.9 | 1960 |
| Sotagliflozin | Lexicon | Zynquista | 200 | 1.8 | 36 |
| Ipragliflozin | Astellas | Suglat | 25, 50 | 7.4 | 1875 |
| Luseogliflozin | Taisho | Lusefi | 2.5, 5 | 2.3 | 3990 |
| Tofogliflozin | Chugai, Kowa | Apleway | 20, 40 | 2.9 | 8444 |
This list of SGLT inhibitors includes the main members of the class approved for routine clinical use in the management of diabetes. Indications vary between regions and prescribers should consult their local product label. IC50 values are approximate. For comparison, phlorizin has an IC50 for SGLT1 of ~ 210 nmol/L and IC50 for SGLT2 of ~ 35 nmol/L
*Dapagliflozin was initially developed by Bristol Myers Squibb and is marketed in Europe as Forxiga